News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Human Genome Sciences, Inc. (HGSI) (JOBS), GlaxoSmithKline (GSK) Report Progress With Lupus Treatment


10/20/2009 7:55:35 AM

Bookmark and Share

WSJ -- Human Genome Sciences Inc. (HGSI) and GlaxoSmithKline PLC (GSK) reported progress in two Phase III trials of belimumab, under investigation as a treatment for seropositive patients with systemic lupus. The drug "plus standard of care achieved a clinically and statistically significant improvement in patient response rate" compared with placebo plus standard of care, the companies, based in Rockville, Md., and London, respectively, said in a statement on Tuesday.

Read at Wall Street Journal
Read at RTT News
Read at Bloomberg


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES